SARASOTA, Fla., Sept. 8, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex Biotherapeutics will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held September 14-16, 2026, in New York City.

Details of the presentation are as follows:

During the conference, Dr. Cooper will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.

About Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.

Contact

Investor Relations

Tiberend Strategic Advisors, Inc.

David Irish

(231) 632-0002

[email protected] 

Media Relations

Tiberend Strategic Advisors, Inc.

Casey McDonald

(646) 577-8520

[email protected] 

SOURCE Lakewood-Amedex Biotherapeutics Inc.

Share this article